Trinity Legacy Partners, LLC Vertex Pharmaceuticals Inc Transaction History
Trinity Legacy Partners, LLC
- $397 Million
- Q2 2025
A detailed history of Trinity Legacy Partners, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Trinity Legacy Partners, LLC holds 480 shares of VRTX stock, worth $186,129. This represents 0.05% of its overall portfolio holdings.
Number of Shares
480
Previous 480
-0.0%
Holding current value
$186,129
Previous $232,000
8.19%
% of portfolio
0.05%
Previous 0.06%
Shares
8 transactions
Others Institutions Holding VRTX
# of Institutions
1,810Shares Held
232MCall Options Held
1.51MPut Options Held
1.08M-
Capital World Investors Los Angeles, CA28.7MShares$11.1 Billion1.94% of portfolio
-
Vanguard Group Inc Valley Forge, PA24MShares$9.3 Billion0.18% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$8.26 Billion0.23% of portfolio
-
Capital Research Global Investors Los Angeles, CA16.1MShares$6.25 Billion1.5% of portfolio
-
State Street Corp Boston, MA11.8MShares$4.57 Billion0.24% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $99.5B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...